ABSTRACT
Introduction
Hydrogen sulfide (H 2 S) has been positioned as the third candidate of the newly emerging "gasotransmitters" family along with nitric oxide (NO) and carbon monoxide (Wang, 2002) . It is produced endogenously from cysteine and homocysteine in reactions catalyzed by cystathionine-␤-synthase and cystathionine-␥-lyase. The expression of these two enzymes is highly tissue-specific. Whereas cystathionine-␥-lyase is largely expressed in the cardiovascular system, cystathionine-␤-synthase predominates in the central nervous system (Chen et al., 1999; Geng et al., 2004b) . H 2 S plays an important role in the regulation of heart function. Together with other groups, we have found that both endogenous and exogenous H 2 S protect the heart from isoproterenol-induced myocardial injury by directly scavenging oxygen free radicals (Geng et al., 2004a) and inhibiting the adenylyl cyclase/ cAMP pathway or L-type calcium channel (Yong et al., 2008b) . Moreover, researchers have found that preconditioning and postconditioning with H 2 S produced cardioprotective effects against ischemic injury via the regulation of protein kinase C, K ATP channels, cyclooxygenase-2, NO, p42/44-mitogen-activated protein kinase, phosphoinositol-3-kinase (PI3K)/Akt, and GSK3␤ pathways Yong et al., 2008a; Yao et al., 2010) . More importantly, endogenous H 2 S was found to contribute to the cardioprotection induced by ischemic preconditioning and postconditioning Pan et al., 2006; Yong et al., 2008a) . In addition, H 2 S may produce a proangiogenic effect (Cai et al., 2007) that can contribute to its cardioprotective action. These results suggest that H 2 S not only ameliorates the pathological process of ischemic heart disease but may also act as a cardioprotective regulator.
Intracellular pH (pH i ) is an important modulator of cardiac function, influencing processes as varied as contraction, excitation, and electrical rhythm. Regulation of pH i is required for the maintenance of an environment appropriate for cellular activities. Hence, pH i has to be tightly controlled within a narrow range, largely through the activity of transporters such as Na ϩ /H ϩ exchanger-1 (NHE-1) and Cl Ϫ /HCO 3 Ϫ exchanger (CBE). Protons are produced metabolically within the heart. These ions are highly reactive with cellular proteins and must be removed if cardiac function is to be maintained. During ischemia, lactic acid accumulation causes significant intracellular acidosis, which stimulates NHE-1. This minimizes intracellular acidosis and causes an increase in intracellular sodium. The protons leaving the cell produce extracellular acidosis. During reperfusion, the extracellular protons are flushed away, and the activity of NHE-1 then leads to a rapid recovery of pH i and a rise in intracellular sodium. The latter could eventually result in Ca 2ϩ entry through the activity of Na ϩ /Ca 2ϩ exchangers. Therefore, it is well accepted that the inhibition of NHE-1 protects against some of the damaging effects of ischemia. We have reported that H 2 S regulates pH i in vascular smooth muscle cells (Lee et al., 2007) and glial cells (Lu et al., 2010a) . Whether or not H 2 S can also regulate pH i in hearts by affecting NHE-1 activity is still unknown. The present study was therefore designed to determine the effect of H 2 S on pH i and NHE-1 activity in isolated cardiac myocytes and investigate whether H 2 S could protect the heart against ischemia/reperfusion via this mechanism.
Materials and Methods
The study protocol was approved by the Institutional Animal Care and Use Committee of National University of Singapore.
Isolation of Rat Ventricular Cardiac Myocytes. SpragueDawley male rats (ϳ190 -210 g) were anesthetized with 200 mg/kg pentobarbitone intraperitoneally. Heparin (1000 IU) was administered intraperitoneally to prevent coagulation during heart removal. The rat hearts were quickly excised and mounted on a Langendorff apparatus. Hearts were then perfused in a retrograde fashion via the aorta with calcium-free Tyrode's solution (137 mM NaCl, 5.4 mM KCl, 1 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose, pH 7.4) at 37°C. After 5 min, the perfusion solution was changed to Tyrode's solution containing 1 mg/ml collagenase type I and 0.28 mg/ml protease (type XIV) and perfused for another 25 to 30 min. The perfusion solution was then changed to Ca 2ϩ -Tyrode's solution containing 0.2 mM CaCl 2 without enzymes for an additional 5 min. The ventricles were then cut into small pieces in a Petri dish containing prewarmed Ca 2ϩ -containing Tyrode's solution and shaken gently to ensure adequate dispersion of the dissociated cardiac myocytes. A 2.5 ϫ 10 Ϫ4 M mesh screen was used to separate the isolated myocytes from cardiac tissue. The cells were then washed three times in Ca 2ϩ -Tyrode's solution and collected by centrifugation (700 rpm, 1 min). Ca 2ϩ concentration was increased gradually to 1.25 mM in 20 min. More than 80% of the cells were rod-shaped and impermeable to Trypan blue. The cells were allowed to stabilize for 30 min before further experimentation. pH i Measurements in Rat Ventricular Cardiac Myocytes. The method of pH i measurement has been described previously (Lee et al., 2007) . In brief, cardiac myocytes were incubated with 1 M 2,7-biscarboxyethyl-5,6-carboxyfluorescein/acetoxymethyl ester (BCECF/ AM) for 30 min in the dark at room temperature. The unincorporated dye was then removed by washing the cardiac myocytes twice in fresh incubation solution. The membrane-permeable ester was trapped inside the myocytes because of hydrolyzation by esterases and fluoresced pH-dependently. The loaded rat cardiac myocytes were kept in the dark at room temperature for another 30 min before pH i measurement to allow the BCECF/AM in the cytosol to de-esterify.
The BCECF/AM-loaded rat cardiac myocytes were transferred to the stage of an inverted microscope (Nikon, Tokyo, Japan) in a perfusion chamber at room temperature. The inverted microscope was coupled with a dual-wavelength excitation spectrofluorometer (Intracellular Imaging Inc., Cincinnati, OH). Cells were perfused with Krebs' solution (117 mM NaCl, 5 mM KCl, 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 1.25 mM CaCl 2 , 25 mM NaHCO 3 , and 11 mM glucose, pH 7.4). Drugs were then added directly into the bath solution during pH i measurements, and the change in fluorescent intensity was monitored. The pH-dependent fluorescent signal of BCECF/AM was obtained by illuminating at excitation wavelengths of 490 nm (F490) and 440 nm (F440). The ratio of signals obtained at F490 and F440 was used to represent pH i . The calibration of BCECF/AM signals was performed by setting pH i to extracellular pH with 10 M nigericin in Krebs' solution. The extracellular pH was changed by perfusion with Krebs' solution at pH 6.8, 7.4, 8, or 10 . From these corresponding pH and fluorescence measurements, a graph was constructed and used for the translation of fluorescence values into pH i values.
Determination of NHE-1 Activity. NHE-1 activity in cardiac myocytes was assessed by measuring the recovery rate of cells from intracellular acidification. Cells were perfused with HEPES-buffered solution containing 137 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.5 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose, adjusted to pH 7.4 with NaOH. Myocytes were maintained at 25°C throughout and subjected to intracellular acidosis by transient exposure to 20 mM NH 4 Cl (6 min at 25°C) with subsequent washout for 8 min. Because NH 4 ϩ enters the cell at a slow, but significant, rate on transporter pathways, this feature is used to acid-load the cytoplasm (Fröhlich and Wallert, 1995) . Washout of NH 4 Cl therefore imposes an acid load by trapping protons into the myocytes. Subsequently, myocytes recovered from this acid load via the activity of NHE-1. The slope of pH i recovery determines the sarcolemmal NHE-1 activity (Fröhlich and Wallert, 1995) . To assess NHE-1 activity of myocytes in the presence of H 2 S, 0.1 mM sodium hydrosulfide (NaHS) was added to the cells 10 min before intracellular alkalinization, followed by perfusion with NaHS-containing HEPES-buffered solution.
Determination of CBE Activity. CBE activity was assessed by measuring the recovery rate of cells from intracellular alkalinization. Intracellular alkalinization was introduced by a rapid addition of 20 mM NH 4 Cl to bathing solution. Exposure of cells to NH 4 Cl results in diffusion of NH 3 across cell membranes, leading to rapid intracellular alkalinization (Furtado, 1987) . pH i gradually decreases from the peak of alkalinization because of the efflux of HCO 3 Ϫ via activity of CBE, that is, a recovery from alkali load (Xu and Spitzer, 1994) . The slope of the pH i decrease determines the rate of recovery from the peak of alkalinization and is measured in ⌬pH/ms. To assess the CBE activity of cells in the presence of H 2 S, 0.1 mM NaHS was added 10 min before intracellular alkalinization, and myocytes were perfused with NaHS-containing HEPES-buffered solution.
Ischemia/Reperfusion in Isolated Rat Ventricular Myocytes. For the cardiac myocyte ischemia/reperfusion experiments,
at ASPET Journals on July 11, 2017 jpet.aspetjournals.org simulated ischemia solution [i.e., glucose-free Krebs buffer containing 10 mM 2-deoxy-D-glucose, an inhibitor of glycolysis, and 10 mM sodium dithionite (Na 2 S 2 O 4 ), an oxygen scavenger, pH 6.6] was applied. The use of simulated ischemia solution in this way produces a mixture of effects including metabolic inhibition, anoxia, and acidosis. This method was adapted from a previous publication (Ho et al., 2002) . In brief, after dissociation, the cardiac ventricular myocytes were allowed to stabilize for 30 min before the experiment commenced. Ventricular myocytes were subjected to ischemia solution for 30 min followed by reperfusion with Dulbecco's modified Eagle's medium solution for up to 1 h. NaHS or cariporide was applied 10 min before and during ischemia, respectively. The viability of cardiac myocytes was determined at the end of reperfusion for a certain period as specified in the individual results. Cell Viability Assay for Rat Ventricular Myocytes. Trypan blue exclusion was used as an index of myocyte viability. At the end of reperfusion, cardiac myocytes were incubated with 0.4% (w/v) Trypan blue dye (Sigma-Aldrich, St. Louis, MO) for 3 min. Those that were unstained were designated as nonblue cells. The ratio of nonblue cells/total cells was determined in a hemocytometer chamber under light microscopy.
PKG Activity Assay. cGMP-dependent protein kinase assay (Cyclex; MBL International, Woburn, MA) was used to measure PKG activity. The isolated cardiac myocytes were divided into different treatment groups: vehicle ϩ ischemia (myocytes treated with vehicle and subjected to simulated ischemia solution for 30 min), NaHS ϩ ischemia (myocytes were pretreated with NaHS at 0.1 mM for 10 min before being subjected to ischemia), Akt VIII ϩ NaHS ϩ ischemia (myocytes were treated with Akt VIII at 1 M for 10 min and then NaHS at 0.1 mM for 10 min followed by ischemia for 30 min), and KR ϩ NaHS ϩ ischemia [myocytes were treated with [5-(2-methyl-5-fluorophenyl)furan-2-ylcarbonyl]guanidine (KR-32568) at 1 M for 10 min and then NaHS at 0.1 mM for 10 min followed by ischemia for 30 min]. Protein extraction was performed in accordance with the manufacturer's instructions (MBL International, Woburn, MA). Experiments of test sample cGMP-minus and ATP-minus groups were conducted as quality controls of our assay.
Western Blotting Analysis. The procedure of detecting Akt phosphorylation by Western blotting was adopted from our previous publication . To examine the effect of NaHS on nonischemic myocytes, the isolated cardiac myocytes were subjected to NaHS or vehicle treatment for 30 min. To test the action of NaHS on cardiac myocytes subjected to ischemic insults, NaHS (0.1 mM) was added to the myocytes for 10 min before and during ischemia for 30 min. To examine the regulatory effect of PKG on Akt phosphorylation, (9S,10R,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3Ј,2Ј,1Ј-kl]pyrrolo[3,4-i][1,6]]enzodiazocine-10-carboxylic acid, methyl ester (KT5823) (0.5 M), a specific inhibitor of PKG, was added 10 min before NaHS treatment. At the end of treatment or ischemia, myocytes were gently washed twice with ice-cold PBS, homogenized in chilled lysis buffer containing 125 mM NaCl, 25 mM Tris, pH 7.5, 5 mM EDTA, 1% nonidet P-40, 1 mM NaF, 2 mM Na 3 VO4, and protease inhibitor (Roche Diagnostics, Indianapolis, IN) and then shaken on ice for 1 h. After that, the lysates were centrifuged at 13,000g for 10 min at 4°C. The supernatants were then collected and denatured by SDS sample buffer, and the epitopes were exposed by boiling the protein samples for 5 min in a dry heat block. Equal amounts of proteins were loaded and separated on 12% SDSpolyacrylamide gel electrophoresis gel, and then transferred onto nitrocellulose membrane. The membrane was then probed with antibodies against phosphorylated and total Akt (1:1000; Cell Signaling Technology, Danvers, MA) and a second antibody. Immunoreactivity was detected by using an ECL Western blot detection kit (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK).
Langendorff Heart Preparation and Hemodynamic Assessment. Hearts were quickly excised, mounted on a Langendorff apparatus, and perfused in a retrograde fashion via the aorta with Kreb's buffer (137 mM NaCl, 2.5 mM CaCl 2 , 5 mM KCl, 1.2 mM MgSO 4 , 10 mM HEPES, and 10 mM glucose, pH 7.4) at 37°C. The hearts were perfused at a constant pressure of 80 mm Hg and subsequently submitted to 40-min stabilization, 30-min global noflow ischemia, and 1-h reperfusion. NaHS or cariporide in Kreb's solution was perfused into the heart for 10 min before global no-flow ischemia was commenced. During the no-flow ischemic period, no solution was perfused. Hearts continued to be exposed to the solution containing NaHS or cariporide during the no-flow ischemic period.
Left ventricular pressure was monitored with a latex balloon connected to a pressure transducer (Powerlab; ADInstruments Pty Ltd., Castle Hill, Australia). The balloon volume was adjusted to obtain a left ventricular end-diastolic pressure (LVEDP) of 5 to 8 mm Hg. All data were digitally converted and stored on a computer for analysis (Powerlab).
Chemicals and Reagents. Nigericin, trans-(Ϯ)-3,4-dichloro-N-
benzeneacetamide methanesulfonate hydrate (U50,488H), NH 4 Cl, NaHS, KR-32568, collagenase I, protease XIV, and Trypan blue dye (0.4%) were purchased from SigmaAldrich. BCECF/AM was obtained from Molecular Probes (Carlsbad, CA). KT5823, Akt VIII, and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) were obtained from Merck Sharp and Dohme (Hoddesdon, UK). Nigericin was dissolved in ethanol. All other chemicals were dissolved in water except KR-32568, KT5823, LY294002, BCECF/AM, and 4,4Ј-diisothiocyanatostilbene-2,2Ј-disulfonic acid, which were dissolved in dimethyl sulfoxide.
Cariporide ([4-isopropyl-3-(methylsulfonyl) benzoyl]guanidine methanesulfonate; HOE-642) was a gift from sanofi-aventis (Frankfurt, Germany). In our preliminary study, we used cariporide at doses of 1, 5, and 7 M to determine the dose-dependent effect on cell viability and NHE activity in the isolated rat cardiac myocytes. We found that cariporide produced significant effects only at a concentration of 7 M. This concentration was used in all further experiments.
NaHS was used as a source of H 2 S. The use of NaHS enabled us to define the concentrations of H 2 S in solution more accurately than bubbling H 2 S gas. NaHS at concentrations used in our work did not change the pH of the medium (Geng et al., 2004b) .
Statistical Analysis. Values presented are mean Ϯ S.E.M. Paired Student's t test was used to determine the difference in fluorescent signal before and after treatment in the same cell. Oneway analysis of variance was used with a post hoc (Bonferroni) test to determine the differences among groups. The significance level was set at P Ͻ 0.05.
Results
Effect of NaHS on pH i in the Rat Ventricular Myocytes. As shown in Fig. 1A , application of NaHS (an H 2 S donor, 100 M), but not Krebs' solution, induced an obvious decrease in pH i in the isolated ventricular myocytes. The effect of H 2 S occurred rapidly after NaHS administration, suggesting that H 2 S readily diffused through the cell membrane and influenced pH i . The decrease in pH i by NaHS mimicked the effect of cariporide (7 M), a selective NHE-1 inhibitor.
The concentration-dependent response is shown in Fig.  1B . NaHS at a concentration range from 10 to 1000 M (yielding approximately 3.3-330 M H 2 S) produced concentration-dependent decreases in pH i in the rat cardiac myocytes. The strongest effect was obtained with NaHS at 100 M. For this reason, 100 M NaHS was applied in the subsequent experiments.
Effect of U50,488H on pH i in the Presence and Absence of NaHS or Cariporide. We had reported previously that U50,488H stimulates NHE-1 activity in cardiac myocytes (Bian et al., 1998) . As shown in Fig. 2A, U50 ,488H at 30 M significantly increased the pH i in the isolated ventricular myocytes. Both cariporide (7 M) and NaHS (100 M) abolished this effect, suggesting that, like cariporide, H 2 S may also inhibit NHE-1 activity.
Effect of NaHS on NHE-1 Activity in Rat Ventricular Myocytes. To verify the involvement of NHE-1 in the action of NaHS, we determined the activity of NHE-1 in cardiac myocytes by measuring the recovery rate of cells from intracellular acidification (Fröhlich and Wallert, 1995) . Figure 3A shows the representative tracings of pH i in three individual ventricular myocytes subjected to intracellular alkalinization by transient exposure to NH 4 Cl. Transient application of NH 4 Cl loaded the cell with alkali, thus inducing a significant elevation in pH i . Subsequent washout with NH 4 Cl induced a strong acid load by trapping protons in the myocytes, thus inducing intracellular acidification. As shown in Fig. 3B , both NaHS and cariporide significantly attenuated the recovery slope of pH i after washout with NH 4 Cl, suggesting that H 2 S decreased NHE-1 activity.
Effect of NaHS on CBE Activity in the Isolated Ventricular Myocytes. Given that CBE is the main acid loader in cardiac myocytes, we also determined its activity by perfusing NH 4 Cl in the presence and absence of NaHS. NH 4 Cl perfusion is a widely adopted method to measure the capacity of CBE to maintain pH i (Xu and Spitzer, 1994) . NH 4 Cl loaded the cells with alkali, resulting in a significant elevation in pH i . As an acid loader, CBE may consequently activate and extrude HCO 3 Ϫ in exchange for Cl Ϫ , which eventually restores the pH i to normal. Therefore, the slope of the pH i recovery phase provides a measure of CBE activity. As shown in Fig. 4 , H 2 S inhibited the activity of CBE. Because inhibition of CBE alone induces intracellular alkalization, instead of acidification, these data indicate that the intracellular acidification induced by H 2 S was mediated by NHE-1 instead of CBE.
Effects of NaHS on Cell Viability in Rat Cardiac Myocytes Subjected to Ischemia/Reperfusion Insults. Because NHE-1 inhibition may protect hearts against ischemia/ reperfusion-induced injury (Karmazyn, 2001) , we further tested whether NaHS could also protect the cardiac myocytes against ischemia/reperfusion injury. The experimental protocol is shown in Fig. 5A and described under Materials and jpet.aspetjournals.org
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Methods. As shown in Fig. 5B , both NaHS and cariporide significantly increased viability of ventricular myocytes subjected to ischemia (30 min)/reperfusion (10 min), suggesting that, like the NHE-1 inhibitor, NaHS may also protect cardiac myocytes against ischemia/reperfusion-induced injury. We further examined the time course for the cardioprotection offered by NaHS. As shown in Fig. 5C , NaHS (100 M) protected cardiac myocytes subjected to ischemia (30 min)/ reperfusion for up to 60 min. These data suggest that the cardioprotective effects of NaHS may last at least 1 h after reperfusion.
To examine whether the effect of NaHS was additive to that caused by NHE-1 inhibition, we compared the cardioprotective effects conferred by treatment with NaHS and KR-32568 (1 M; another potent NHE-1 inhibitor) alone or in combination (NaHS ϩ KR-32568). As shown in Fig. 5D , NaHS produced comparable protective effects to those caused by KR-32568 alone and in combination treatment. These data suggest that H 2 S and the NHE-1 inhibitor were not synergistic.
The Effect of NaHS on NHE-1 Activity Is Mediated by PI3K/Akt and Protein Kinase G Pathways. Because activation of PI3K/Akt (Snabaitis et al., 2008) or PKG (Pérez et al., 2007) inhibits NHE-1 activity, we examined whether the effect of H 2 S involves these pathways. As shown in Fig. 6A , blockade of PI3K with LY294002 (1 M) or PKG with KT5823 (0.5 M) (neither of which had a significant effect on NHE-1 activity) produced marked attenuation of the inhibitory effect of NaHS on NHE-1 activity. These data suggest that the activation of PI3K/Akt and PKG may somehow be involved in the inhibitory effect of NaHS on NHE-1 activity.
We then investigated the effect of NaHS on PKG by measuring its activity with a semiquantitative immunoassay kit. As shown in Fig. 6B , NaHS significantly increased the PKG activity in the myocytes subjected to ischemia. Pretreatment with Akt VIII, the Akt inhibitor, but not KR-32568 (1 M), an Moreover, pretreatment with KT5823 for 10 min failed to attenuate NaHS-stimulated Akt phosphorylation (Fig. 6C) . The similar effect was also observed under ischemic conditions. Ischemia for 30 min significantly down-regulated Akt phosphorylation. This effect was reversed by NaHS (100 M) pretreatment for 10 min. Blockade of PKG with KT5823 also failed to attenuate the effect of H 2 S on Akt phosphorylation during ischemia (Fig. 6D) . Taken together, our data clearly suggest that the Effect of NaHS on cell viability in cardiac myocytes subjected to ischemia/reperfusion (I/R). A, experimental protocol. The cardiac myocytes were treated with vehicle, NaHS (100 M), or cariporide (7 M) for 10 min before and during the simulated ischemia. After ischemia for 30 min, the simulated ischemia buffer was washed out with fresh Dulbecco's modified Eagle's medium solution, and cell viability was measured at the end of reperfusion with a Trypan blue exclusion assay. B, both NaHS and cariporide significantly increased the cell viability of cardiac myocytes subjected to ischemia (30 min)/reperfusion (10 min). C, group data show the protective effects of NaHS against the cardiac myocytes injury induced by ischemia and reperfusion for 10, 30, and 60 min. D, treatment with NaHS (100 M) and KR (KR-32568; 1 M) alone or a combination of both protected myocytes against ischemia/reperfusion insult to a similar extent. Mean Ϯ S.E.M. (n ϭ 4 -6). #, P Ͻ 0.05 versus the vehicle-treated group. ‫,ء‬ p Ͻ 0.05; ‫,ءءء‬ p Ͻ 0.001 versus the corresponding value in the control group. †, P Ͻ 0.05; † †, P Ͻ 0.01 versus the corresponding value in the group of myocytes subjected to ischemia/reperfusion injury. . ‫,ء‬ p Ͻ 0.01 versus control. †, P Ͻ 0.05; † †, p Ͻ 0.01 versus the NaHStreated group. B, PKG activity in the isolated cardiac myocytes was determined with a semiquantitative immunoassay kit. Group data were obtained from five independent experiments. ‫,ء‬ P Ͻ 0.01 versus ischemia group. † † †, P Ͻ 0.001 versus NaHS plus ischemia group. C and D, effect of NaHS (100 M) on Akt phosphorylation in cardiac myocytes in the presence or absence of KT5823 (0.5 M; KT) in normal (C) and ischemic (D) cardiac myocytes. Pretreatment with KT5823 for 10 min failed to affect the stimulatory effect of NaHS on Akt phosphorylation in cardiac myocytes. The cardiac myocytes were pretreated with NaHS for 10 min and remained in contact with NaHS during ischemia for 30 min. At the end of ischemia, the myocytes were harvested and subjected to Western blot analysis. The representative gels show the levels of phosphorylated Akt (p-Akt) and total Akt (t-Akt) in the myocytes subjected to various treatments. Mean Ϯ S.E.M. (n ϭ 8). #, p Ͻ 0.05; ##, p Ͻ 0.01 versus vehicle-treated myocytes without ischemia. † † †, P Ͻ 0.001 versus vehicletreated myocytes subjected to ischemia.
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at ASPET Journals on July 11, 2017 jpet.aspetjournals.org activation of PKG is secondary to the NaHS-induced Akt activation but is upstream to NHE-1 inhibition. The Effects of NaHS on Postischemic Recovery of Left Ventricular Function during Ischemia/Reperfusion Are Mediated by the PI3K/Akt/PKG/NHE-1 Pathway. We also examined the effect of NaHS on the contractile function of isolated heart during ischemic reperfusion. As shown in Fig. 7 , during the preischemic period, all measured parameters such as left ventricular developed pressure (LVDP), LVEDP, and maximum and minimum rate of developed pressure (ϮdP/dt) were comparable among the groups. Representative tracings of control, NaHS (100 M), and cariporide (7 M), are shown in Fig. 7A . Time-dependent changes in LVDP (Fig. 7B) , LVEDP (Fig. 7C) , and ϮdP/dt (Fig. 7, D and E) in the control, NaHS, and cariporide treatment groups are shown. Treatment with NaHS and cariporide at 5, 10, and 15 min of reperfusion improved the postischemic contractile function significantly, compared with the untreated hearts (control).
We further confirmed that the cardioprotection offered by NaHS is mediated by the PI3K/Akt/PKG pathway. As shown in Fig. 8 , the effects of NaHS on LVDP and Ϯdp/dt in the isolated hearts subjected to ischemia/reperfusion were also alleviated by LY294002 (1 M; a PI3K inhibitor), Akt VIII (1 M; a specific Akt inhibitor), and KT5823 (0.5 M; a PKG inhibitor). These data suggest that NaHS-induced cardioprotection is, at least partly, mediated by the PI3K/Akt and PKG pathways. It is interesting to note that the blockade of PI3K/ Akt or PKG had no significant effect on NaHS-induced protection on LVEDP. These data imply that the protective effects of NaHS may not be solely mediated by these signaling pathways.
Discussion
pH i is a fundamental modulator of protein function in cells (Zaniboni et al., 2003) . In the heart, pH i influences contractility (Vaughan-Jones et al., 1987; Kohmoto et al., 1990) and affects the generation of arrhythmias (Orchard and Cingolani, 1994; Ch'en et al., 1998) . Previous studies from ours and Fig. 7 . Effect of NaHS on the contractile function of isolated hearts subjected to ischemic reperfusion. NaHS or cariporide in Krebs' solution was perfused into heart for 10 min before global no-flow ischemia (30 min) was commenced. The hearts remained in contact with NaHS and cariporide during ischemia. The heart was then subjected to reperfusion for a period of time. Representative tracings (A) and group data (B, LVDP; C, LVEDP; D, ϩdP/ dT; E, ϪdP/dT) show that the perfusion of NaHS or cariporide significantly improved heart contractile function. Mean Ϯ S.E.M. (n ϭ 3-7). ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001 versus the corresponding vales in the preischemia group. other groups have found that H 2 S plays a critical role in protecting the heart against ischemic injury (Geng et al., 2004a,b) . In the present study, we investigated the effect of H 2 S on pH i in the cardiac myocytes and the underlying mechanisms. We found that NaHS over a concentration range of 10 to 1000 M decreased pH i in a concentrationdependent manner.
In the present study, U50488H was used as a tool compound to stimulate NHE. U50488H is a -opioid receptor agonist. At lower concentrations (Ͻ10 M), it produces cardioprotective effects via activation of PI3K/Akt and suppression of cAMP/PKA pathways (Yu et al., 1999; Wang et al., 2001; Kim et al., 2011) . However, at higher concentrations (ϳ30 M or higher), it induces intracellular alkalization and cardiac arrhythmias via stimulation of protein kinase C/NHE pathways (Yu et al., 1999; Bian et al., 2000) . We found that NaHS abolished the U50,488H-stimulated intracellular alkalization. The NHE activity assay further confirms that H 2 S-induced intracellular acidosis is mediated by inhibition of NHE-1 activity.
NHE-1 is an important acid extruder in cells. It is well recognized that NHE-1 inhibition may produce cardioprotection. We also found in the present study that both NaHS and NHE-1 inhibitor protected hearts against ischemic injury. However, the combination of two drugs did not produce any additive or synergistic cardioprotective effect. Our study therefore suggests that NaHS produced cardioprotection via the inhibition of NHE-1 activity.
The signaling mechanism for the action of H 2 S on NHE-1 was also investigated. It has been reported previously that the activation of Akt phosphorylates NHE-1 and thus inhibits its activity (Snabaitis et al., 2008) . We therefore tested whether the inhibition of NHE-1 activity caused by H 2 S is mediated by the PI3K/Akt pathway. We found that NaHS treatment stimulated Akt phosphorylation in both normal and ischemic cardiac myocytes. Our finding is in agreement with a report that H 2 S protects cardiac myocytes from hypoxia/reoxygenation-induced apoptosis via stimulation of Akt phosphorylation (Yao et al., 2010) . Moreover, blockade of PI3K with LY294002 or Akt with Akt VIII significantly attenuated the inhibitory effect by NaHS on NHE-1 activity and its subsequent cardioprotection. To confirm the contribution of the PI3K/Akt pathway, we also observed the protective action of NaHS on heart contractile function in the presence or absence of Akt VIII, a specific inhibitor of Akt. Like LY294002, Akt VIII also attenuated the effect of H 2 S on cardiac contractile function. These data suggest that the cardioprotection of H 2 S involves the PI3K/Akt/NHE-1 pathway. It is noteworthy that recent studies showed that the inhibition of NHE-1 may also stimulate Akt (Jung et al., , all of which alone had no effect, significantly attenuated the effects of H 2 S on heart contractile function. Inhibitors were given 10 min before the addition of NaHS for 10 min followed by no flow ischemia. Mean Ϯ S.E.M. (n ϭ 5-9). ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001 versus the corresponding values in the control group. ϩ, p Ͻ 0.05; ϩϩ, p Ͻ 0.01 versus the corresponding values in the NaHS-treated group. 2010). These data suggest that the activation of Akt and inhibition of NHE-1 may be codependent. In addition to Akt activation, Yao et al. (2010) found H 2 S inhibited GSK3␤ and subsequently inhibited the opening of mitochondrial permeability transition pore (mPTP). NHE-1 inhibition was also noted to produce cardioprotection via the phosphorylation and inhibition of GSK3␤ (Jung et al., 2010 ). These findings suggest that H 2 S may inhibit GSK3␤ through the inhibition of NHE-1 activity.
NHE-1 activity can also be regulated by PKG. A previous study showed that blockade of PKG restored the suppressed NHE-1 activity to normal (Pé rez et al., 2007) . We therefore examined the involvement of PKG on the actions of NaHS. We found that blockade of PKG with KT5823 attenuated the effect of NaHS on NHE-1 activity and its protective effects on postischemia-induced contractile function injury. This implies that PKG may also be involved in the regulation of NHE-1 activity by NaHS. This was verified by the PKG activity assay. In fact, NaHS treatment enhanced PKG activity in ischemic cardiac myocytes. Moreover, the increase of PKG activity could be blocked by the Akt inhibitor, indicating that Akt is upstream of PKG activation. The failure of the PKG inhibitor, KT5823, to attenuate NaHS-stimulated Akt activation again supports the evidence that the activation of PKG is secondary to PI3K/Akt activation.
CBE is the major acid loader in the cardiovascular myocyte. Stimulation of this transporter would be expected to "dampen" the ability of the cell to maintain a normal pH i range and therefore decrease pH i . For this reason, we also observed the effect of H 2 S on CBE activity. We found that H 2 S inhibits, but not stimulates, CBE. These data exclude the possibility that CBE contributes to the action of H 2 S in regulating pH i in the cardiac myocytes.
The mechanisms for cardioprotection resulting from NHE-1 inhibition have been well studied previously. Ischemia-induced protons leaving the myocytes via NHE-1 during reperfusion may lead to Na ϩ loading, which may subsequently induce Ca 2ϩ overloading as Na ϩ leaves the cell via the Na ϩ /Ca 2ϩ exchanger. The resultant rise in intracellular calcium concentration is believed to trigger Ca 2ϩ -activated proteases and phospholipases that cause cellular damage (Tani, 1990; Pierce and Czubryt, 1995) . In addition, ischemia/reperfusion may open mPTP to disrupt the permeability barrier of the inner membrane. This will result in mitochondrial swelling and cause the outer membrane of mitochondria to break. The rupture of the outer membrane will lead to the release of proteins in the intermembrane space such as cytochrome c, apoptosis-inducing factor, and other factors that play a critical role in apoptotic cell death. Once released, these factors activate caspase-9, which in turn activates caspase-3. This protease mediates the proteolytic cleavage of a range of proteins responsible for the rearrangement of the cytoskeleton, plasma membrane, and nucleus that are characteristic of apoptosis. A potent inhibitor of mPTP opening is low pH (Halestrap et al., 2004) . Therefore, in this way, NHE1inhibition produces cardioprotection.
However, despite the great promise of cardioprotection offered by NHE inhibitors from extensive preclinical work , clinical studies have not been as convincing. It was found that direct and global NHE inhibition may trigger noncardiac adverse effects. Compared with NHE inhibitors, H 2 S may have better clinical application potential. This is because, apart from inhibition of NHE-1, H 2 S also protects the heart via suppression of ␤-adrenoceptor function and stimulation of various protein kinases and cardioprotective mediators such as prostaglandin E 2 and NO Hu et al., 2008; Pan et al., 2008 Pan et al., , 2009 Yong et al., 2008b) . In addition, H 2 S has been found to be useful in treating renin-dependent hypertension (Lu et al., 2010b) , chronic heart failure (Calvert et al., 2010) , and hypertrophy (Shi et al., 2007) . These data suggest that H 2 S treatment may provide multiple cardioprotective effects. However, bearing in mind that the NHE inhibitors were not very successful in clinical development for cardioprotection despite the great promise shown in preclinical studies, the outcome of this preclinical study does not rule out the possibility of failed clinical application of H 2 S in ischemic heart conditions. Clinical investigations are thus warranted to confirm the usefulness of H 2 S.
In summary, we demonstrate in the present study that H 2 S decreases pH i in cardiac myocytes by inhibiting NHE-1 activity via a PI3K/Akt/PKG-dependent mechanism. This further offers cardioprotective effects against ischemia/reperfusion-induced injury. The unique action of H 2 S suggests a potential therapeutic application for its use in ischemic conditions of the heart.
